Posters

• P01-01 • HPV16 minority variants among cervical and anal samples with single HPV16 or multiple HPV types infections See abstract > C. Charlotte CHARPENTIER • P01-02 • Detection of cervical human papillomavirus in women attending cervical cancer screening by visual inspection in Côte d’Ivoire See abstract > A. Abdoulaye OUATTARA • P02-01 • Detection of high-risk HPV DNA in chagasic megaesophagus with and without cancer See abstract > F. Fernanda Franco MUNARI • P02-02 • Comparative study of HPV prevalence in glans and urine between the patients with prostate cancer and benign prostatic hyperplasia See abstract > K. Kazuyoshi SHIGEHARA • P02-03 • HPV prevalence 10 years after vaccine introduction in Germany- design of a population-based study in 20-25 year-old women See abstract > A. Anja TAKLA • P02-04 • Trends in rates of treated RRP before and after HPV vaccination among New York children See abstract > L. Lauren CASS • P02-05 • Epidemiology of cervical cancer in a region of Southern Algeria See abstract > Z. Zakia Batoul BENLAHRECH • P02-06 • Increasing trends in the incidence of potentially human papillomavirus-associated head and neck cancer in Italy (1988-2012) See abstract > P. Paolo BOSCOLO-RIZZO • P02-07 • Cervical cancer in situ among women aged above 60 who was adequately screened at 50s, and the potential of progressing to invasive cervical cancer See abstract > J. Jiagrong WANG • P02-08 • Age-specific additional impact of a nonavalent HPV vaccine on precancerous squamous cervical lesions in Spain See abstract > S. Sonia PEREZ • P02-09 • HPV viral load correlations among young, recently-formed heterosexual couples See abstract > M. Michel WISSING • P02-10 • The onset of oral sex, human papillomavirus and oropharyngeal cancers See abstract > C. Claudie LAPRISE • P02-11 • The prognostic role of detection and genotyping of HPV in penile carcinoma See abstract > V. Vera SADDI • P02-12 • Recent increase in cervical cancer incidence in Sweden 2014-2015 See abstract > B. Bengt ANDRAE • P02-13 • Screening history and the risk of invasive cervical cancer in women aged 66 and older See abstract > L. Lin JIAN-JHIH • P02-14 • Pilot prevalence of incidence of 12 genotype of high risk HPV and 2 genotype of low risk HPV in Khorasan Razavi Stateς See abstract > M. Mofrad HASANZADEH • P03-01 • Presence of HPV in Inverted Papilloma See abstract > A. Alexandra ELLIOT • P04-01 • HPV-specific B and T-cell responses in vaccinated and non-vaccinated young women See abstract > H. Hella PASMANS • P04-02 • Hr-HPV L1,E1, E2, E6, E7 seropositivity does not predict anal HSIL among HIV-positive men who have sex with men See abstract > M. Maarten SCHIM VAN DER LOEFF • P04-03 • Serotype and genetic diversity of human papillomavirus 58 in Italian women with low-grade cytology See abstract > A. Anna GODI • P05-01 • Human papillomavirus prevalence and genotype distribution in urine samples from vaccinated as compared to non-vaccinated females in Norway See abstract > L. Lill TROGSTAD • P05-02 • Potential impact of the 9vHPV vaccine in South Korea: an overview See abstract > Y. Youngtak KIM • P05-03 • Safety and efficacy of a quadrivalent human papillomavirus vaccine against persistent infection and genital diseases in Chinese women during a 78-month follow-up See abstract > L. Lihui WEI • P05-04 • Potential of HPV vaccination in cancer control See abstract > L. Lise Holst THAMSBORG • P05-05 • HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway See abstract > B. Berit FEIRING • P05-06 • HPV vaccination of adolescent girls is not associated with sexual activity initiation and risky sexual behaviours See abstract > C. Chantal SAUVAGEAU • P05-07 • Cross-protective effectiveness of AS04-HPV-16/18 vaccination in reducing cervical HPV infections in adolescent girls- results from a community-randomized trial See abstract > F. Frank STRUYF • P05-08 • HPV See abstract > H. Haddy BAH CAMARA • P05-09 • Mother to infant transfer of anti HPV 6 and 11 antibodies upon immunization with the 9VHPV vaccine. See abstract > A. Amita JOSHI • P05-09 • Mother to infant transfer of anti HPV 6 and 11 antibodies upon immunization with the 9VHPV vaccine. See abstract > A. Amita JOSHI • P07-01 • Efficacy of a coriolus versicolor-based vaginal gel to repair cervical mucosa with HPV lesions. Interim analysis results See abstract > L. Luis SERRANO • P07-01 • Efficacy of a coriolus versicolor-based vaginal gel to repair cervical mucosa with HPV lesions. Interim analysis results See abstract > L. Luis SERRANO • P07-02 • Efficacy of a coriolus versicolor- based vaginal gel to clear HPV. Interim analysis results See abstract > Y. Yann GASLAIN • P07-03 • Use of coriolus versicolor-based vaginal gel in patients with precancerous HPV lesions. Interim analysis results See abstract > J. Josep COMBALIA • P07-04 • Effect of a non-hormonal coriolus versicolor vaginal gel among positive-HPV women with no colposcopy cervical lesions. A pilot study See abstract > C. Carine EMSELLEM • P08-01 • Papilloplex ™ Hr HPV – a novel multiplex assay for detection and genotyping of all 14 Hr HPV types in a single closed-tube real-time PCR reaction See abstract > G. Guoliang FU • P08-02 • Development and validation of HPV test intended for use in cervical cancer screening “AmpliSens HPV HCR screen-titr-14-FL See abstract > M. Marina DMITRYUKOVA • P08-03 • Mass spectrometry as a reliable high throughput technology for routine HPV diagnostics See abstract > P. Petra WANDERNOTH • P08-04 • Comparison of mRNA and DNA HPV levels in hrHPV-positive primary screening samples using digital droplet PCR See abstract > G. Gabriella LILLSUNDE LARSSON • P08-05 • Population-based HPV Testing Performance: Comparison HC2 and Cervista HPV Testing Assays See abstract > M. Ming GUO • P08-06 • Significantly higher risk for high-grade cervical lesions in follow-up biopsy associated with positive Aptima HPV tests than Cobas tests See abstract > Y. Yimin GE • P08-07 • HPV test in cytology laboratory practice- a ten year experience See abstract > D. Damjana VERSA OSTOJIC • P08-08 • A highly efficient assay for detection of high-risk HPV E7 proteins in cervical samples See abstract > I. Isabel KOCH • P08-09 • Xpert®HPV testing on BD-Surepath® medium fixed liquid based cytology specimen: performance evaluation compared to HC2 tests results See abstract > P. Pauline LE VAN QUYEN • P08-10 • Hr-HPV testing on formalin fixed paraffin embedded (FFPE) samples: performance evaluation of Xpert®HPV versus PCR Inno-lipa ® extra II genotyping and P16 IHC on 28 head and neck carcinomas See abstract > F. François FASQUELLE • P08-11 • HPV testing for cervical cancer screening: experience in Centro Medicina Laboratorial Germano de Sousa/ Hospital Cuf Descobertas See abstract > A. Ana ALBUQUERQUE • P08-12 • In-house liquid based medium validation for hrHPV detection with Hybrid Capture 2 (HC2), QIAGEN See abstract > N. Nataša NOLDE • P08-13 • Onclarity in the diagnosis of patients with cervical lesion: comparison with HC2 and linear array See abstract > F. Fabio BOTTARI • P08-14 • Comparison of Seegene Anyplex II HPV 28 detection and Abbott Realtime High Risk HPV test on NOVAprep liquid-based cytology media See abstract > S. Sébastien HANTZ • P08-15 • Methylation of WIF1 gene and microRNA expression in diagnosis of HPV-associated squamous intraepithelial lesions and squamous cervical cancer See abstract > G. Guldana BAYRAMOVA • P08-16 • Diagnostic excision of cervix in women with persistent HPV infection with no former evidence of CIN in cytology See abstract > R. Riina AARNIO • P08-17 • Are non-vaccine replacing vaccine genotypes in young women targeted by vaccination programs? A trend analysis from opportunistic screening in Luxembourg See abstract > A. Ardashel LATSUZBAIA • P09-01 • New scenarios of HPV screening – Georgian experience See abstract > E. Ekaternia KLDIASHVILI • P09-02 • Age distribution and risk progression of HSIL and higher lesions in the Puerto Rican population in 2015 See abstract > V. Vanessa SANCHEZ • P09-03 • Accurate detection of human papillomaviruses by PNA mediated real time PCR using melting curve analysis See abstract > B. Bora CHOI • P09-04 • Comparison of p16/Ki67 dual immunocytochemical staining, HPV testing and cytology results obtained in three cytopathology laboratories participating in Slovenian cervical cancer screening program ZORA See abstract > V. Veronika KLOBOVES PREVODNIK • P09-05 • HPV focal: 48 month colposcopy compliance and time to colposcopy based on referral screen result See abstract > L. Laurie SMITH • P09-06 • Positive predictive value of HPV screen tests and HPV 16/18 genotyping at baseline and 48 months in the HPV focal trial See abstract > D. Darrel COOK • P09-07 • High-grade squamous intraepithelial lesions with negative HPV testing See abstract > E. Ester DURAN ARBONÉS • P09-08 • Randomized health care policy evaluation of organised primary HPV screening of women aged 56-60 See abstract > H. Helena LAMIN • P09-09 • Evaluation of the impact of the hr-HPV based cervical cancer screening: results of a four-years experience in a single screening center of Italy See abstract > C. Claudio DI CRISTOFANO • P09-10 • Organized cervical cancer-screening program in Brazil: Barretos experience in 18 municipality of São Paulo state See abstract > F. Fabiana Lima VAZQUEZ • P09-11 • Cervical screening and risk assessment using multiplexed protein assay See abstract > P. Peter GOMBRICH • P10-01 • Cervical cancer and precancerous lesions screening in rural area’s women by HPV detection using self-sampled tests See abstract > N. Naitielle DE PAULA PANTANO • P10-02 • HPV DNA self-sampling offers a valid tool for cervical cancer screening in Kinshasa, the Democratic Republic of Congo See abstract > C. Catherine ALI-RISASI • P10-03 • For high-risk HPV testing the sensitivity of a urine sample equals that of a self-collected vaginal sample See abstract > M. Marianne WALDSTRØM • P10-04 • A pilot study of community based self sampling for high risk human papillomavirus test in Chinese population See abstract > M. Man Kin CHUNG • P10-05 • The cost-effectiveness of HPV self-sampling for non-attenders in a Danish cervical cancer screening program See abstract > C. Caitlin ASJES • P10-06 • EVALUATION OF THE ROCHE COBAS® 6800 HPV ASSAY WITH COLLI-PEE® COLLECTED, UCM PRESERVED URINE. See abstract > V. Vanessa Vankerckhoven • P11-01 • The 5-year incidence and clearance of type-specific HPV in a screening cohort in China > R. Remila REZHAKE • P11-02 • HPV genotyping in ASC-US cytology at Rio de Janeiro, Brazil See abstract > F. Filomena SILVEIRA • P11-03 • A comparison study of the INNO-LiPA and the Linear Array HPV genotyping tests See abstract > I. Irene Tveiteras OVESTAD • P11-04 • Evaluation of the persistence of HPV genotypes in women treated for CIN2+ lesions See abstract > M. Maria Teresa SANDRI • P11-05 • HPV type specific distribution in women attending routine cervical screening in rural Malawi See abstract • P11-06 • Burden of cervical HPV infection and genotype distribution among women attending two rural health centers in the Gondar region of Ethiopia See abstract > S. Solomon Behre WUBNEH • P11-07 • Genotyping of human papillomavirus in triaging of low-grade cervical cytology See abstract > C. Carla LECUMBERRI • P11-08 • HPV L1 genetic diversity variants in strains from Northeastern Mexican patients and the discrepancy results obtained by real time PCR See abstract > M. Mariel OYERVIDES-MUNOZ • P12-01 • Diagnostic value of HPV16 and HPV18 viral load and integration status among African women infected with HIV See abstract > M-N. Marie-Noëlle DIDELOT-ROUSSEAU • P12-02 • The use of p16/Ki-67 dual staining technology on cervical cytology of patients undergoing a LLETZ procedure See abstract > B. Bram PACKET • P12-03 • Analysis of the influence of p16 in the inter and intra observer concordance in the diagnosis of intraepithelial neoplasia of cervix grade 2 (CIN2) See abstract > A. Ana FORTEZA • P12-04 • Proteomic composition of cervicovaginal fluid in HPV-associated cervical lesions See abstract > V. Vera PRILEPSKAYA • P12-05 • Detection of cervical (pre)cancer on the basis of cervicovaginal fluid: possibilities for development of a selftest See abstract > D. Daisy VERSWIJVEL • P12-06 • Clinical utility of p16INK4a as a diagnostic adjunct for underlying CIN2+ cervical lesions See abstract > A. Annabelle FERRERA BOZA • P12-07 • Modern multidisciplinary monitoring of cervical cancer risk See abstract > R. Roxana Elena BOHILTEA • P12-08 • Methylation of inhibitors WNT signaling pathway and HPV types in cervical cancer See abstract > S. Silvia Helena RABELO-SANTOS • P12-09 • An MRNA panel for triage of HPV positive women with high specificity for detection of clinically relevant cervical disease See abstract > S. Sarah HOWIE • P13-01 • What is the positive predictive value of high-grade squamous intraepithelial lesion (HSIL) on cytology for the histological diagnosis of cervical intraepithelial neoplasia 2 (CIN2) or more? A systematic review See abstract > J. Johannes BOGERS • P13-02 • Comparison of HPV positivity of vaginal samples harvested by gynecologist and patient herself in Japan See abstract > K. Kazufumi NAKASHIMA • P13-03 • Discordant results between oncogenic human papillomavirus RNA and DNA tests in a contesting cervical cancer screening program See abstract > A. Alicia SÁEZ • P13-04 • Upgrading of information system for management and monitoring of Slovenian cervical cancer screening programme See abstract > U. Urska IVANUS • P13-05 • Economic analysis of a strategy to improve cervical cancer screening in Denmark: Cytology with HPV triage vs. primary HPV screening with cytology and CINtec PLUS cytology triage See abstract > M. Margrethe KOFOD • P13-06 • Role of HPV viral loads in guiding biopsy under colposcopy for ASC-US and HPV positive women See abstract > X. Xiao Qian XU • P13-07 • Evolution of the cervical cancer screening program in the Western half of the province of Huesca (Spain) between 2010-16 See abstract > J. José Manuel RAMON Y CAJAL • P13-08 • The implementation of HPV based screening in Australia: sustainable workforce implications See abstract > V. Vincent WILLIAMS • P13-09 • Is a three-year cytological screening cervical cancer safe and is it important for possible early treatment of premalignant intraepithelial lesions? See abstract > R. Radomir ŽIVADINOVIC • P13-10 • Compare Two Different Usages of the FRD™ for Detecting High Grade Cervical Lesions and Invasive Cancer See abstract > D. Donghong LI • P13-11 • The Significance of the Epithelium Staining Applicator in Cervical Staining with the FRD™ See abstract > D. Donghong LI • P13-12 • The diagnostic value of lugol solution, acetic acid, and Pap smear compared to biopsy regarding premalignant and malignant cervical lesions diagnosis in patients in need of colposcopy See abstract > M. Mojgan KARIMI-ZACHI • P14-01 • HPV analysis improves the PPV of Atypical Glandular Cells See abstract > I. Ingrid NORMAN • P16-01 • Evaluation of a host DNA methylation panel in a high HPV prevalence cohort See abstract > C. Carlos SOUSA • P16-02 • Biological risk factors associated with methylation positive and negative high-grade cervical lesions – clinical study See abstract > K. Katerina CERNA • P17-01 • The interaction between HPV infection and bacterial microbiota in placenta, cervix and oral mucosa See abstract > H. Heidi TUOMINEN • P17-02 • Vaginal microbiota and PAP smear See abstract > A. Anni VIRTANEN • P18-01 • Development and validation of an optimized HPV competitive Luminex immunoassay (9-PLEX) and HPV IgG antibody detection Luminex immunoassay ( 9-PLEX) supporting clinical serology testing for Gardasil-9 See abstract > K. Katrina NOLAN • P19-01 • A new generation of validity testing for oncoprotein-based cervical cancer screening See abstract > C. Christine REICHHUBER • P19-02 • Establishment of three-dimensional organotypic raft cultures closely mimicking HPV-transformed cervical lesions in an epithelial context See abstract > R. Richard KOEHLER • P20-01 • Retrospective study of sensitivity, specificity, positive predictive value of cytology in liquid medium, HPV DNA test and genotyping for HPV16, in different cervical cancer screening scenes See abstract > F. Francisco Javier QUEIPO GUTIERREZ • P20-02 • Conization using electrosurgical conization with cold coagulation for cervical intraepithelial neoplasia: a feasible treatment with a low risk of residual disease See abstract > S-Y. Seo-Yeon KIM • P20-03 • Evaluation and correlation of primary histopathological diagnosis of targeted biopsy till the final histopathological diagnosis following diagnostic and therapeutic process of leep conization See abstract > D. Dominik PRUSKI • P20-04 • What’s behind LSILs? See abstract > C. Carla RODRIGUES • P20-05 • Cytological changes in women under 25 years See abstract > C. Carla RODRIGUES • P21-01 • Colposcopy Evaluation at the Time of LEEP May Avoid Unnecessary Treatment See abstract > M. Meritxell MUNMANY • P21-02 • Improving clinical practice: the European Federation of Colposcopy quality standards in a colposcopy clinic See abstract > A. André KIND